A series of microbiota were correlated inversely with the disease severity and virus load. Gut microbiota could play a role in modulating host immune response and potentially influence disease severity and outcomes.
Coronavirus can target multiple organs due to the hyperactive immune response with cytokine storms. Several studies have detected SARS-CoV-2 in stool samples and indicated that the virus could spread via faeces. Importantly, COVID-19 uses the same receptor as SARS and this doorway can also be found in the intestine. The cell entry receptor, known as angiotensin converting enzyme 2 (ACE2) receptor mediate entry of SARS-CoV-2 and is highly expressed in small bowel enterocytes. ACE2 is important in controlling intestinal inflammation and its disruption may lead to diarrhoea. In our previous study, stool samples from 15 patients with COVID-19 were analysed. Depleted symbionts and gut dysbiosis were noted even after patients were detected negative of SARS-CoV-2. A series of microbiota were correlated inversely with the disease severity and virus load. Gut microbiota could play a role in modulating host immune response and potentially influence disease severity and outcomes. In July 2020, there are more than 15 billion confirmed cases globally with 620 thousand deaths. Currently, there are more than 2000 confirmed cases of COVID-19 in Hong Kong. It is important to rebalance the gut microbiota in COVID-19 patients and to improve the symptoms and the quality of life of these patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
20
tailor-made Synbiotics, 4g per day for 28 days
Chinese University of Hong Kong
Hong Kong, Hong Kong
RECRUITINGChanges in gut microbiome
Changes in the gut microbiome (bacteria, virome and fungome) measured by metagenomics at week 5 compared to baseline
Time frame: week 5
Changes in fecal bacteria metabolites
Changes in fecal bacteria metabolites by PCR at different time points
Time frame: weeks 2, 4, 5, 8 and months 3, 6, 9 and 12
Change in plasma cytokines including IL-6, IL-IB, TNF-a and CXCL-10
Change in plasma cytokines level at week 5 compared with baseline
Time frame: week 5
Trend in symptom score
Trend of symptom score at different time points, ranges from 26-104. The higher the score, the worse the symptoms.
Time frame: weeks 2, 4, 5, 8 and months 3, 6, 9 and 12
Change in Quality of life measured by EQ-5D-5L
Change in score on Quality of life using EQ-5D-5L at different time points. EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The index can be calculated by deducting the appropriate weights from 1, the value for full health (i.e. state 11111). Each category ranges from 1 to 5. The small the number, the better the health. The EQ-VAS is a vertical visual analogue scale that ranges 0-100 (higher score indicates better imaginable health).
Time frame: weeks 2, 4, 5, 8 and months 3, 6, 9 and 12
Change in Quality of life measured by SF-12
Change in score on Quality of life using SF-12 at different time points. SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. There are formulas for transformation of scale scores so that they will range from 0-100. High score in functioning items indicates better functioning while high score in pain items indicates freedom from pain.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: weeks 2, 4, 5, 8 and months 3, 6, 9 and 12
Duration of gastrointestinal symptoms
Duration of gastrointestinal symptoms such as anorexia, nausea, vomiting, abdominal pain, bloating within 4 weeks.
Time frame: 4 weeks
Adverse event assessment
Number of adverse event
Time frame: 3 months